

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/68	A1	(11) International Publication Number: WO 93/05182 (43) International Publication Date: 18 March 1993 (18.03.93)
(21) International Application Number: PCT/US92/07489 (22) International Filing Date: 4 September 1992 (04.09.92) (30) Priority data: 755,485 5 September 1991 (05.09.91) US (60) Parent Application or Grant (63) Related by Continuation US 755,485 (CIP) Filed on 5 September 1991 (05.09.91) (71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only) : BRUICE, Thomas, W. [US/US]; 6880 Shearwater Drive, Carlsbad, CA 92009 (US). (74) Agents: CALDWELL, John, W. et al.; Woodcock Wash- burn Kurtz Mackiewicz & Norris, One Liberty Place, 46th Floor, Philadelphia, PA 19103-7301 (US). (81) Designated States: AU, BR, CA, FI, HU, JP, KR, NO, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report.</i>
(54) Title: DETERMINATION OF OLIGONUCLEOTIDES FOR THERAPEUTICS, DIAGNOSTICS AND RESEARCH REAGENTS (57) Abstract Oligonucleotides which selectively bind to target biomolecules may be determined by <i>in vitro</i> assay of a pool of random oligonucleotides for activity against said biomolecules, followed by recovery and characterization of selected oligonucleotides. Oligonucleotides so determined may be utilized for therapeutic, diagnostic and research reagent purposes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

WO 93/05182

PCT/US92/07489

-1-

**DETERMINATION OF OLIGONUCLEOTIDES FOR
THERAPEUTICS, DIAGNOSTICS AND RESEARCH REAGENTS**

FIELD OF THE INVENTION

This invention relates to *in vitro* selection of oligonucleotide sequences which selectively bind to a target biomolecule under physiological conditions. In accordance with preferred embodiments, therapeutic oligonucleotides are identified.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation -in-part of U.S. Serial No. 755,485 filed September 5, 1991 and entitled "Determination of Oligonucleotides for Therapeutics, Diagnostics and Research Reagents" which is assigned to the assignee of the present application and incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

The development of new drugs and biologically active substances for therapeutic, diagnostic and research reagent purposes traditionally concentrates on development of such compositions based upon knowledge of the target biomolecule, or molecule to be modulated.

Bodily states in mammals, including many disease states, are effected by biomolecules. Classical therapeutics has generally focused upon interactions with proteins in efforts to modulate disease-potentiating functions of such proteins. In addition to modulating disease potentiating functions of proteins directly, recent attempts have been made to moderate the actual production

WO 93/05182

PCT/US92/07489

- 2 -

of proteins by interactions with molecules that direct their synthesis, intracellular RNA. Biological functions may also be modulated or regulated by interactions with other biomolecules such as nucleic acids, carbohydrates, lipids, steroids or toxins.

One approach for constructing therapeutics, diagnostics and research reagents has been simple modifications of known amino acid or nucleic acid sequences. Such techniques are limiting because the number of individual sequences of simple modifications necessary for the development of new substances is prohibitively large. In addition, many drug targets and other target molecules are too extensive and complex to be analyzed by these mutational experiments. Other biomolecule targets, by virtue of their particular chemical nature, are not candidates for directed mutagenesis of this sort. Some examples of such biomolecules are carbohydrates, lipids, and steroids.

Recently, methods have been devised whereby therapeutics, diagnostics and research reagents can be developed more quickly. A variety of combinatorial strategies have been described to identify active peptides. Houghton, et al. *Nature* 1991, 354, 84; Lam, et al., *Nature* 1991, 354, 82; Owens, et al., *Biochem. Biophys. Res. Commun.* 1991, 181, 402; Fodor, et al., *Science* 1991, 251, 767; Geysen, et al., *Molecular Immunology* 1986, 23, 709; Zuckermann, et al., *Proc. Natl. Acad. Sci.* 1992, 89, 4505; Rutter, et al., U.S. 5,010,175 issued April 23, 1991; Lam, et al., PCT US91/06444 filed July 1, 1991.

Rutter, et al. describes a method whereby statistically randomized peptides may be prepared and active peptide selected for and identified.

Lam, et al., teaches the preparation of randomer libraries, especially random peptide libraries in which each randomer sequence is individually coupled to a solid support (i.e. one oligomer sequence/one bead). Further, a reporter group is attached to each oligomer/bead in order

WO 93/05182

PCT/US92/07489

- 3 -

to identify active oligomers from inactive oligomers. The randomer libraries of Lam, et al. are then contacted with a target biomolecule and active randomers identified via reporter groups, are isolated using the solid support to manually remove the active randomer from the rest of the library. Lam, et al. further teaches that the selected randomer can be characterized such as by Edman degradation or FAB-MS. Randomer oligonucleotide libraries are also mentioned by Lam, et al. Characterization of selected oligonucleotides after manually separation is suggested by the techniques of Maxam and Gilbert or by the use of an oligonucleotide sequencer. Electrospray-high performance mass spectrometry is also suggested in order to determine sequences and structures of randomers. This methods required the addition of a reporter group to the oligomer species in order to identify and manually isolate active oligomers. Furthermore, randomer libraries are limited to oligomers approximately 5mers in length since preparation of more than 5mers would present unwieldy amounts of oligomer/beads as well as the need for large amounts of target.

Focusing on the field of combinatorial nucleic acid selection methods, methods generally select for a specific nucleic acid sequence from a pool of random nucleic acid sequences based on the ability of the selected sequence to bind to a target protein. The selected sequences are then commonly amplified and the selection process repeated until a few strongly binding sequences are identified. Commonly, the pool of random nucleic acid sequences is comprised of short random sequences embedded internally in external, flanking or "carrier" nucleic acid molecules of known sequence. Such carrier molecules are intended to neither enhance, nor detract from binding of the oligonucleotide. The amplification primers are prepared to be complementary to known sequences of the "carrier" generally of lengths 20 nucleotides in length or more. Such "carrier" portions are meant to facilitate

WO 93/05182

PCT/US92/07489

- 4 -

manipulation of the molecule and preferably have neutral effect upon the randomized sequence to be selected for. Using this method Tuerk and Gold, *Science* 1990, 249, 505; identified a sequence which strongly binds T4 polymerase binding protein, gp43, but which would not have been predictable using traditional methods. Ellington and Szostak, *Nature* 1990, 346, 818; identified sequences which bind small ligands using this method and Bock, et al., *Nature* 1992, 355, 564 designed DNA molecules which recognize the protease thrombin.

While some advantages have been achieved by the foregoing methods, simple methods of determining therapeutics, diagnostics, and research reagents are desirable. Previous methods have relied upon complex nucleic acid molecules comprised of at least partially random sequence portions to be selected for, as well as lengthy flanking carrier portions necessary to support the reactions. Still other methods are limited in the length of oligonucleotides within the randomer library which are physically possible.

Methods in which selection may be carried out with a fully sequence randomized pool of discrete molecules comprised primarily of the sequences to be selected for would be greatly desirable as they would increase specificity, facilitate manipulation of the pool of molecules, and eliminate any indeterminate bias in binding selection resulting from the presence of either internal sequence fixed (unrandomized) positions and/or the carrier portions.

Methods to determine oligonucleotides for antisense therapeutics, diagnostics and research reagents carried out with discrete, non-biased molecules, are greatly desired.

Although oligonucleotides are currently being investigated as potential therapeutic agents, it is not known *a priori* how to select an ideal nucleotide sequence to bind selectively to a target molecule. Moreover, in

WO 93/05182

PCT/US92/07489

- 5 -

many cases, it is even difficult to decide what region of a gene or protein, for example, to target in order to achieve maximum effect. The methods of the present invention overcome these difficulties.

5 SUMMARY OF THE INVENTION

In accordance with some embodiments of the present invention, methods of determining oligonucleotides having specific activity for a target biomolecule are provided. In accordance with said methods a set of
10 randomized oligonucleotides may be prepared and assayed for activity against the target biomolecule. Active and inactive oligonucleotides are separated by microanalytical techniques and the active oligonucleotides are characterized by microanalytical structural determination.

15 In other embodiments of the present invention, oligonucleotides having specific activity for a target biomolecule are determined by preparing a set of randomized oligonucleotides and assaying the set of random oligonucleotides for activity against a target biomolecule.
20 Active and inactive oligonucleotides are separated and active oligonucleotides are recovered. Thereafter active oligonucleotides are amplified by extending a polyA sequence in a 3' direction on active oligonucleotide. A first chimeric primer comprising a 5' known sequence and a
25 3' polydT portion may be hybridized to the oligonucleotide and a cDNA strand may be prepared which is complementary to the oligonucleotide using the first chimeric primer. The cDNA may be extended in a 3' direction by the addition of polyA. Thereafter, the oligonucleotide and cDNA strands
30 are separated and a second chimeric primer having a 5' known sequence and a 3' polydT portion is hybridized to the polyA portion of the cDNA resulting in the formation of recessed 3' ends on both strands. The recessed ends may be filled to form two complementary strands and the strands
35 separated and amplified using polymerase chain reaction. The first and second chimeric primers may serve as PCR

WO 93/05182

PCT/US92/07489

- 6 -

primers in some embodiments of the present invention. Furthermore, the oligonucleotide starting product, having been amplified, may be excised from the total PCR product and may be recovered and used in subsequent assay and

5 amplification steps in order to optimize determination of oligonucleotides specifically active for a given target biomolecule.

In accordance with other methods of the present invention methods of determining oligonucleotides having

10 specific activity for a target biomolecule are provided comprising the steps of preparing a set of randomized oligonucleotides and assaying the set of randomized oligonucleotides for activity against a target biomolecule. Active oligonucleotides are separated from inactive

15 oligonucleotides and recovered. Recovered oligonucleotides are characterizing to provide an oligonucleotide cassette. Thereafter a set of oligonucleotides comprising an oligonucleotide cassette and at least one flanking region of randomized positions are prepared and assayed for

20 activity against a target biomolecule. Active oligonucleotide are separated from inactive oligonucleotides and active oligonucleotides are recovered. Thereafter the recovered oligonucleotides are characterized to provide a new oligonucleotide cassette. This new

25 oligonucleotide cassette may be used in subsequent preparation, assay and characterization steps in order to optimize determination of oligonucleotides specifically active for a given target biomolecule.

In yet further embodiments of the present

30 invention sets of sequence position randomized oligonucleotides may be subfractionated and assayed for activity for a target biomolecule. Oligonucleotides from the subfraction having the highest activity for a the biomolecule may then be assayed, separated from inactive

35 oligonucleotides and characterized in accordance with methods of the invention.

WO 93/05182

PCT/US92/07489

- 7 -

In other embodiments of the present invention methods of amplifying oligonucleotides are provided. PolyA may be extended in a 3' direction on the oligonucleotide to be amplified. A first chimeric primer comprising a 5' known sequence and a 3' polydT portion may be hybridized to the oligonucleotide and a cDNA strand may be prepared which is complementary to the oligonucleotide using the first chimeric primer as a primer. The cDNA may be extended in a 3' direction by the addition of polyA. Thereafter, the oligonucleotide and cDNA strands are separated and a second chimeric primer having a 5' known sequence and a 3' polydT portion is hybridized to the polyA portion of the cDNA resulting in the formation of recessed 3' ends on both strands. The recessed ends may be filled to form two complementary strands and the strands separated and amplified using polymerase chain reaction. The first and second chimeric primers may serve as PCR primers in some embodiments of the present invention.

Oligonucleotides identified in accordance with the methods of the present invention are also encompassed by the present invention. Oligonucleotides identified and sequenced in accordance with methods of the present invention are likewise encompassed by the present invention. In accordance with other embodiments of the present invention diagnostic and research reagents are provided.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Methods of determining oligonucleotides that are specifically active against target biomolecules are provided. In the context of the present invention "determine" refers to the identification of the sequence of oligonucleotides and the binding activity of the oligonucleotides for a target molecule. Further, "determine" refers to the identification of oligonucleotides having activity such as catalytic or

WO 93/05182

PCT/US92/07489

- 8 -

enzymatic activity. In some instances, neither the oligonucleotide sequence nor its specific activity is known prior to performance of methods of the present invention. In other cases, while a particular oligonucleotide sequence
5 may be known, those skilled in the art may not recognize its activity for a particular target molecule. In still other cases, activity of a known sequence for a particular target molecule may be optimized.

In some embodiments of the present invention,
10 "specific activity" refers to binding affinity of said oligonucleotides for a target molecule. In other embodiments of the present invention, specific activity encompasses binding affinity and further encompasses activity such as catalytic or enzymatic activity. As used
15 herein, binding affinity refers to the ability of the oligomer to bind to a target molecule via hydrogen bonds, van der Waals interactions, hydrophobic interactions, or otherwise. For example, an oligonucleotide may have binding affinity for another oligonucleotide to which it is
20 complementary, i.e., to which it has the ability to hybridize due to Watson-Crick base pair attraction. Thus active oligonucleotides have specific activity, be it binding, catalytic, enzymatic, or other activity for a target molecule, while inactive oligonucleotides exhibit
25 minimal or no specific activity for a target biomolecule. The amount of activity sufficient to differentiate an active oligonucleotide from an inactive oligonucleotide will, of course, vary depending upon the parameters of the assay and the biomolecule targeted.

30 In accordance with said methods randomized oligonucleotides are prepared. In the context of this invention, the term "oligonucleotide" refers to a polynucleotide formed from naturally occurring bases and furanosyl groups joined by native phosphodiester bonds.
35 This term effectively refers to naturally occurring species or synthetic species formed from naturally occurring subunits or their close homologs. The term

WO 93/05182

PCT/US92/07489

- 9 -

"oligonucleotide" may also refer to moieties which have portions similar to naturally occurring oligonucleotides but which have non-naturally occurring portions. Thus, oligonucleotides may have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur-containing species which are known for use in the art. In accordance with some preferred embodiments, at least some of the phosphodiester bonds of the oligonucleotide have been substituted with a structure which functions to enhance the stability of the oligonucleotide or the ability of the oligonucleotide to penetrate into the region of cells where the viral RNA is located. It is preferred that such substitutions comprise phosphorothioate bonds, phosphotriesters, methyl phosphonate bonds, short chain alkyl or cycloalkyl structures or short chain heteroatomic or heterocyclic structures. Most preferred are $\text{CH}_2\text{-NH-O-CH}_2$, $\text{CH}_2\text{-N(CH}_3\text{)-O-CH}_2$, $\text{CH}_2\text{-O-N(CH}_3\text{)-CH}_2$, $\text{CH}_2\text{-N(CH}_3\text{)-N(CH}_3\text{)-CH}_2$ and $\text{O-N(CH}_3\text{)-CH}_2\text{-CH}_2$ structures. Also preferred are morpholino structures. Summerton, J.E. and Weller, D.D., U.S. 5,034,506 issued July 23, 1991. In other preferred embodiments, such as the protein-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to an aza nitrogen atoms within the polyamide backbone. P.E. Nielsen, et al., *Science* 1991 254 1497. In accordance with other preferred embodiments, the phosphodiester bonds are substituted with other structures which are, at once, substantially non-ionic and non-chiral, or with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in practice of the invention.

Oligonucleotides may also include species which include at least some modified base forms. Thus, purines and pyrimidines other than those normally found in nature may be so employed. Similarly, modifications on the

WO 93/05182

PCT/US92/07489

- 10 -

furanosyl portion of the nucleotide subunits may also be effected, as long as the essential tenets of this invention are adhered to. Examples of such modifications are 2'-O-alkyl- and 2'-halogen-substituted nucleotides. Some

5 specific examples of modifications at the 2' position of sugar moieties which are useful in the present invention are OH, SH, SCH₃, F, OCN, O(CH₂)_nNH₂, O(CH₂)_nCH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl, Br, CN, CF₃, OCF₃, O-, S-, or

10 N-alkyl; O-, S-, or N-alkenyl; SOCH₃, SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an

15 oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. Sugar mimetics such as cyclobutyls may also be used in place of the pentofuranosyl group. Oligonucleotides may also comprise

20 other modifications consistent with the spirit of this invention. Such oligonucleotides are best described as being functionally interchangeable with, yet structurally distinct from, natural oligonucleotides. All such oligonucleotides are comprehended by this invention so long as

25 they effectively function as subunits in the oligonucleotide.

The term "random", as used herein, is used in the sense of oligonucleotides having truly random base sequence, formed through solid state synthesis. This

30 method need not, however, be completely and statistically random in fact. Thus, enrichment of oligonucleotides in certain bases may be desired in accordance with some embodiments of this invention. In the context of the present invention a random oligonucleotide pool or library

35 is a set of oligonucleotides having sequences representing every possible combination of nucleotide units within the randomized positions. Thus, in accordance with the present

WO 93/05182

PCT/US92/07489

- 11 -

invention an oligonucleotide may have a complexity of P^N where P is the number of different units used and N is the number of positions in an oligonucleotide which are randomized. For example, an oligonucleotide pool of
5 oligonucleotides having six random positions comprising four different subunits would have a complexity of 4^6 or 4096 different sequences representing every possible combination of subunits. Of course, a randomer pool may not necessarily be random in fact, and enrichment of
10 oligonucleotides in certain bases may be desired in accordance with some embodiments of this invention.

Unlike the preparation of randomized peptide libraries which have large degrees of incorporation bias away from the molar ratio of the premixed unit members,
15 Rutter and Santi, U.S. #5,010,175 issued April 23, 1991, the coupling efficiencies of natural nucleotide units and of analogs of limited chemical diversity using commercially available automated synthesizers and standard phosphoramidite chemistry known to those skilled in the art
20 appears to be very similar. That is, near equimolar incorporation at a given randomized position of all monomer unit members of an equimolar mixture is obtained for randomized libraries of sufficient total quantity and limited complexity. Thus, in accordance with preferred
25 embodiments of the present invention, columns of a DNA synthesizer may be packed with a mixture containing an equal amount of adenosine(A)-, cytidine(C)-, guanosine(G)- and uracil(U) (or thymidine(T))-controlled pore glass (CPG, Chemgenes, Needham, MA). At each "random" coupling step,
30 an equimolar mixture of all four phosphoramidites may be delivered to each column. Nucleic acid synthesizers are commercially available and their use is generally understood by persons of ordinary skill in the art to generate nearly any oligonucleotide of reasonable length
35 which may be desired. In some preferred embodiments of the present invention the sequence randomized oligonucleotides

WO 93/05182

PCT/US92/07489

- 12 -

are cleaved from the controlled pore glass to provide a pool of sequence randomized oligonucleotides in solution.

Randomized oligonucleotides made using monomer groups having greater sequence and structure complexity may
5 require appropriate premixture ratio correction factors in order to obtain equimolar incorporation of any monomer unit in the presence of any other monomer units at randomized sequence positions of combinatorial libraries of the present invention. Strategies to determine coupling
10 efficiencies and to correct for any observed coupling bias are known to those skilled in the art. For example, Rutter and Santi, U.S. #5,010,175 issued April 23, 1991 and Lam, et al., PCT US91/06444 filed July 1, 1991, describe strategies to accommodate incorporation bias in randomer
15 peptide libraries.

In some embodiments of the present invention oligonucleotide groups may be detectably labeled. Reporter groups can be incorporated as polymerizable monomer units such as phosphoramidites, usually at the 3' or 5' ends of
20 the oligonucleotides. Labelling may also be performed following completion of combinatorial library synthesis such as by chemical modification such as post-synthesis conjugation. Radiolabels such as ^3H , ^{14}C , ^{35}S , ^{32}P , ^{33}P and ^{18}O may be incorporated by methods known to those skilled in
25 the art. Furthermore, fluorescent, chemoluminescent, spin-label, and redox reactive (i.e. for electrochemical detection) groups are commonly employed by those skilled in the art. For example, an oligonucleotide group may be labeled at the 5' termini of the oligonucleotides using [γ -
30 ^{32}P] ATP and T4 polynucleotide kinase. One skilled in the art would recognize that differential bias caused by the incorporation of such a label should be avoided. Thus, in some embodiments of the present invention each individual sequence member of the combinatorial pool is labeled
35 identically. It should be further recognized that the reporter group may contribute to the specific activity of an oligonucleotide. Thus, the reporter group may be

WO 93/05182

PCT/US92/07489

- 13 -

treated as another monomer unit analog and permanently incorporated into the composition.

Oligonucleotides of the present invention may be of predetermined length. It is preferred that such
5 oligomers be from about 6 to about 50 units in length. It is more preferred that such oligomers be from 12 to about 20 units in length.

In some aspects of the present invention oligonucleotides may be in solution. In other aspects of
10 the invention sequence randomized oligonucleotides may be bound to solid support without sequence preference.

There is a complexity limit to the detectability of specific activity (signal to noise), especially in longer oligonucleotide libraries composed of larger numbers
15 of chemically distinct monomer units in which the oligonucleotides have a high percentage of randomized positions. It is likely that with short, i.e. 8-10 nucleotides in length, unstructured, conformationally dynamic oligonucleotides, such as might commonly be used to
20 initially limit complexity to facilitate identification of highest specific activity sequences, a plethora of relatively weak specific activity towards many target molecules will result. Procedures useful for increasing the complexity of an oligonucleotide pool and for
25 increasing the specific activity of oligonucleotide pool are encompassed by the present invention.

The use of additional units such as nucleotide analogs may be preferred in some instances where it is desirable to increase the complexity of the group of
30 oligonucleotides, thereby increasing the specific activity. The complexity of a group of random oligonucleotides is represented by the formula P^N where P is the number of different units used and N is the number of positions in an oligonucleotide which are randomized. Table 1 illustrates
35 the change in group complexity as a result of the increase in the number of analogs used.

WO 93/05182

PCT/US92/07489

- 14 -

TABLE I

Oligonucleotide: NNNNNN

	Number of different analogues used (P)	Complexity of each set (Q) (P ⁶)
5	4	4 ⁶ = 4096
	5	5 ⁶ = 15,625
	6	6 ⁶ = 46,656
	7	7 ⁶ = 117,649
	8	8 ⁶ = 262,144
10	9	9 ⁶ = 531,441
	10	10 ⁶ = 1,000,000

Initial screening protocols may be useful to determine whether a given monomer unit or analog will have a positive, negative or neutral effect in a given library pool for a pre-chosen target. Determination can be made by incorporating equimolar amounts of all chosen monomer units at every position of a pool and comparing the specific activity of the pool for a target molecule to the specific activity of a combinatorial pool prepared without the monomer unit in question.

An additional method of increasing the specific activity of a group of oligonucleotides is to constrain the oligonucleotide conformationally in order to provide the correct presentation of the randomer oligonucleotide for the target biomolecule. There are two general classes of conformationally constrained chemistries, noncovalent and covalent. Noncovalent bonding is generally easier as it can be achieved without additional chemistry steps. For example, an oligonucleotide may be conformationally constrained by providing short complementary ends at the 3' and 5' termini of the region of interest, which region of interest comprises randomized positions. Generally the complementary ends range in length from about 3 to about 8 nucleotides in length. The complementary ends will hybridize to form secondary structure thereby providing correct presentation of the randomized portion of the oligonucleotide to the target biomolecule. In accordance with other aspects of the invention, noncovalent

WO 93/05182

PCT/US92/07489

- 15 -

conformational constraints may be achieved with physiologic divalent metal bridge chelation of the 5' and 3' ends of oligonucleotides.

Covalent constraints may also be provided by the
5 incorporation of complementary reactive groups at different fixed positions in the oligonucleotides of the combinatorial library. This may result in spontaneous unique covalent bond formation to form crosslinks, under the appropriate reaction conditions which will be apparent
10 to those skilled in the art. Reactive groups and nucleotide analogs useful in the formation of crosslinking groups are described for example, by U.S. Serial No. 846,376 filed March 5, 1992 and incorporated by reference herein in its entirety.

15 Detectable specific activity may also be enhanced by a sequential method in which evolutions of oligonucleotide pools, each of greater complexity than its predecessors, are assayed for specific activity and characterized. This methods allows selection in a
20 randomized environment within a complexity limit that is easily handled. Thus, for example, during one round of determination performed in accordance with methods of the present invention an oligonucleotide specific for a target biomolecule is identified from a random pool of
25 oligonucleotides. Thereafter, a next pool of longer oligonucleotides may be prepared capitalizing upon the oligonucleotide sequence determined in the previous step (i.e. a cassette) by incorporation of the determined sequence or cassette into the sequence of the pool to
30 provide a pool of oligonucleotides having at least one cassette and at least one flanking region of unrandomized positions. Thereafter the pool of oligonucleotides is assayed for specific activity for a target biomolecule, and the sequence of the active oligonucleotide or
35 oligonucleotides is determined. This procedure may be performed iteratively, building the oligonucleotides of

WO 93/05182

PCT/US92/07489

- 16 -

each new round based upon the determined sequences from the previous step or steps.

In some embodiments of the present invention it may also be desirable to subfractionate a pool of sequence randomized oligonucleotides to provide subfractions of the oligonucleotide pool, thus delimiting the degree of complexity of each subfraction that is assayed at one time. This both diminishes the amount of total material that must be used in a determination in order to have sufficient representation of all individual sequences and it also enhances the signal to noise ratio of the assay by starting with an oligonucleotide subfraction enriched in the most active sequences. Any physical-chemical or functional characteristic, combined with an appropriate separation modality may be used to empirically subfractionate a group, thereby resulting in (or deriving) numerous distinct subfractions of diverse character, and diminished complexity. It is theorized that if a particular fit sequence or sequences exist within the original group for a particular target, it will be found enriched in a limited number of the reduced complexity subfractions.

One skilled in the art would be apprised of the broad selection of appropriate selection modalities which are available. The strategy followed will of course depend upon the properties of the elements of the oligonucleotide pool. It will further be appreciated by one skilled in the art that as the number of group elements increases and the structural and chemical diversity enlarges, there will be a greater selection of separation strategies leading to increased subfractionation capacity. By way of example, it is envisioned that novel oligomers may be resolved into subfractions by any one or a combination of size, positive or negative charge, hydrophobicity and affinity interactions. Many chromatographic and analytical instrumental methods are known to those skilled in the art which may be effectively applied to the separation strategies encompassed herein.

WO 93/05182

PCT/US92/07489

- 17 -

Target molecules of the present invention may include any of a variety of biologically significant molecules. By biologically significant, one skilled in the art would understand that molecules inherently related to some biological function are intended. In addition, biological significance need not be limited to disease related significance, but may also mean significance to, for example, the greater understanding of biological functions, or the greater ability to monitor or control normal biological function. Target molecules may be nucleic acid strands such as significant regions of DNA or RNA. Target molecules may also be proteins, carbohydrates, lipids, toxins, steroids, drugs or cofactors. In some preferred embodiments of the present invention, said target molecule is a protein such as an immunoglobulin, receptor, receptor binding ligand, antigen or enzyme and more specifically may be a phospholipase, tumor necrosis factor, endotoxin, interleukin, plasminogen activator, protein kinase, cell adhesion molecule, lipoxxygenase, hydrolase or transacylase. In other preferred embodiments of the present invention said target molecules may be important regions of DNA or RNA of the human immunodeficiency virus, *Candida*, herpes viruses, papillomaviruses, cytomegalovirus, rhinoviruses, hepatitises, or influenza viruses. In still further preferred embodiments of the present invention said target molecule is ras 47-mer stem loop RNA, the TAR element of human immunodeficiency virus, the gag-pol stem loop of human immunodeficiency virus (HIV), the RRE element of HIV or the HIV tat protein. Still other targets may induce cellular activity. For example, a target may induce interferon.

In some aspects of the present invention, a target protein may be identified based upon the fact that proteins bind to free aldehyde groups while nucleic acids do not. Thus, a sampling of proteins which have been identified as potential targets may be bound to solid supports having free aldehyde groups such as nitrocellulose

WO 93/05182

PCT/US92/07489

- 18 -

filters. For example, up to 96 proteins may be bound in individual wells of a 96-well nitrocellulose filter manifold. In some embodiments of the present invention sequential concentrations of protein may be tested to

5 determine the effect of lowering the protein target concentration. Thereafter, an identical detectably labeled oligonucleotide group may be incubated with each protein sample under binding conditions. The preparation of labeled oligonucleotide groups is described herein. The

10 support is washed and the presence or absence of binding is detected whereby binding indicates that the oligonucleotide group has specific activity for a given protein. As will be apparent to one skilled in the art, methods of detection of binding will be dependent upon the label used.

15 Specific activity of oligonucleotides of the present invention may be detected by methods known to those skilled in the art. At least a portion of the random oligonucleotide pool will most preferably have specific activity for a target molecule. The remaining

20 oligonucleotides may be separated from the active oligonucleotides such as by methods disclosed herein. Appropriate assays will be apparent to one skilled in the art and oligomer concentration, target molecule concentration, salt concentration, temperature, buffer and

25 buffer concentration may be altered to optimize a particular system. Initial assay conditions should preferably be compatible with further steps in the procedure. For example, high concentrations of salt or reagents which may interfere with binding should be avoided

30 in some embodiments of the invention. In some preferred embodiments of the present invention, binding conditions simulate physiological conditions. In other preferred embodiments of the present invention binding occurs in a buffer of from about 80 mM to about 110 mM sodium chloride

35 and from about 10 to about 15 mM magnesium chloride. Oligomers may also generally be assayed for catalytic or enzymatic activity.

WO 93/05182

PCT/US92/07489

- 19 -

Gel shift assays may be used to visualize binding of an oligomer to a target molecule and separate bound from unbound oligonucleotides. In accordance with methods of the present invention, radiolabelled target molecule bound to oligomer of the present invention may be run on a gel such as a polyacrylamide gel. Bound target molecule has less mobility than unbound target molecule, and therefore will not migrate as far on the gel. The radioactive label allows visualization of the "shift" in mobility by standard procedures for example, by means of X-ray radiography or by using a phosphorimager (Molecular Dynamics). In other embodiments of the present invention a gel shift assay may be performed wherein an unlabeled target molecule may be detected preferentially bound to radiolabeled oligonucleotide selected from the sequence randomized oligonucleotide pool.

Streptavidin-biotin capture is another useful assay for the detection of specific activity and separation of active oligonucleotide from inactive oligonucleotides. A target may be biotinylated prior to incubation with a radioactively labeled random oligonucleotide pool. Biotinylation of target is a well known procedure which may be accomplished through a number of known procedures. For example, an RNA target may be biotinylated using 5' kinase reactions. The oligonucleotide pool is thereafter incubated with the target and the target molecule is captured on streptavidin-coated solid support. Consequently any oligonucleotide which bound to the target will also be captured. Any of a broad range of solid supports known in the art could effectively be used in methods of the invention. For example, streptavidin-coated solid supports are available commercially such as for example, streptavidin-coated magnetic beads available from Promega (Madison, WI) and streptavidin coated microtitre plates (Covalink) available from NUNC (Raskilde, Denmark) or Labsystems (Marlboro, MA). The solid support may be washed

WO 93/05182

PCT/US92/07489

- 20 -

and the reaction may be reequilibrated to further enrich the "winning" sequence.

Techniques such as continuous flow mass transport methodologies (Giddings, J. Calvin, *Unified Separation Science*, John Wiley and Sons, Inc., New York, 1991) may be also performed to identify active oligonucleotides and separate active from inactive oligonucleotides. Any of a broad range of methodologies which involve the use of continuous, differential mass transport flow via multiple competing equilibria between interacting species in a system with sufficient resolving power are envisioned for use in effecting desired resolution. Such methodologies must preserve and take advantage selectively of $k_{\text{dissociation}}$ for the tightest complexes being the slowest of all competing on and off rate constants. Furthermore, selected methodologies must achieve high stringency separation while enhancing enrichment of bound complexes. Optimally the amount of target molecule should be much greater than the amount of individual sequences, but should not be greater than the amount of the total number of oligonucleotide sequences in the combinatorial library used. This formula will allow some limited competition of all individual sequences for binding to the target, yet there will be sufficient target to retain most of the preferred oligonucleotide. What will allow success is the provision of enough resolving capacity and power to handle the relative and absolute concentrations and mass amounts of all components and the differential affinity of their interactions according to the performance characteristics of the particular systems. (Giddings, *Unified Separation Science*, John Wiley and Sons, Inc., New York, 1991). Separation methodologies dependent on nonspecific physical-chemical properties may be employed. Preferred methodologies include those methodologies in which specific affinity interactions are utilized such as solid support based affinity chromatography wherein the target molecule is stably attached to a solid support and the ligands are

WO 93/05182

PCT/US92/07489

- 21 -

in the flowing mobile phase. High specificity affinity separation can also be achieved when both the target molecule and the ligand pool are in the mobile phase. Forces effecting differential transport of bound target and free ligands is all that is required. Resolution may also be enhanced by the inclusion of a mass excess (over the randomized oligonucleotide ligand pool) of a uniformly nonspecific, weak binding molecule (such as bovine serum albumin) of the ligand pool that does not interact with the target molecule.

Representative resolution modalities which may be useful in methods of the present invention include, but are not limited to, size exclusion/gel filtration chromatography (Sephadex-LPLC or Superous-FPLC), isoelectric focusing (IEF) including Rotofor IEF (Bio-Rad), fast affinity chromatography (Beckman), electrophoresis methods, sedimentation methods, field flow fractionation (FFF), ion exchange chromatography, weak affinity chromatography; Zopf and Ohlson, *Nature*, 1990, 346, 87; affinity filtration, centrifugal countercurrent chromatography (CCC), perfusion chromatography, affinity chromatography on solid supports, and hydrophilic interaction chromatography.

Microanalytical resolution techniques may also be employed to separate active from inactive oligonucleotides. In some embodiments of the present invention microanalytical separation techniques may also be useful to resolve a group of active oligonucleotides. Microanalytical resolution technologies are well known in the art and any of the technologies will be useful in the present invention. For example, gas chromatography (gc), high performance liquid chromatography (HPLC), high performance capillary electrophoresis (HPEC), and field flow fractionation (FFF), (Giddings, J. Calvin, *Unified Separation Science*, John Wiley and Sons, Inc., New York, 1991), may be used alone or on-line with microanalytical characterization technologies. HPLC methods have evolved

WO 93/05182

PCT/US92/07489

- 22 -

to accommodate the resolution of nanomole and lesser quantities of materials. For example, microbore HPLC on-line with mass spectrometry has been applied to resolve a combinatorial problem. Hunt, et al., *Science*, 1992, 255, 1261. HP capillary electrophoresis (HPCE) may also be effectively applied to resolve oligonucleotides. When HPCE is placed on-line with mass spectrometry there is no requirement to be able to directly resolve sequences prior to injection in the mass spectrometer. Use of this methodology is described in Toulas, et al., *LC-GC*, 1992, 10, 471 (detection of attomolar to zeptomolar amounts of fluorescence reporter group tagged oligonucleotides with laser-induced fluorescence detection); Rodrigues, et al., *Amer. Biotech. Lab.* 1992, 21, (capillary non-gel sieving electrophoresis of nucleic acids); Carchon, et al., *Amer. Biotech. Lab.* 1992, 67; Stevenson, *Amer. Lab.* 1992, 17; Stevenson, *Chem. and Engin. News*, 1992, 24, (micellar electrokinetic capillary electrophoresis); Cobb, et al., *Anal. Chem.* 1992 (mapping and sequence determination of pre-fragmented oligomers from HPCE). Two dimensional electrophoresis of oligonucleotides may also be useful, especially where oligonucleotides are comprised of chemically diverse monomers.

Assays are not limited to detecting binding affinity but may also detect other desired activities such as biological responses such as catalytic or enzymatic activity. It should be recognized that functional activities are always mediated by prior binding interactions. Thus, selection for function is also selection for binding.

Positive functional selection is preferred in some embodiments of the present invention. For example, selection for catalytic function may be achieved by covalently coupling the moiety containing a scissile bond to be bound and cleaved to a solid support with a noncleavable linker and via a group on the opposite side of said cleavable bond, by coupling also to one end of

WO 93/05182

PCT/US92/07489

- 23 -

oligonucleotides of the combinatorial pool. The pool is thus covalently coupled to the solid support via the intermediate substrate containing the bond to be cleaved. Only those sequences in the pool capable of binding to the substrate and cleaving the only reactive bond present will release themselves from covalent capture on the solid support. These sequences may then be recovered from the solution phase and characterized. In the alternative, only those sequences that catalyze bond formation will bind covalently to the solid support via a reversible linker. The non-bound oligonucleotides may be washed away and the reversible linker cleaved to release the active sequences. Solid supports, noncleavable and reversible linkers and attendant conjugation chemistry are well known in the art.

In accordance with methods of the present invention active oligonucleotides are recovered. Recovery of active oligonucleotides, as used herein, refers to sufficient purification of the active oligonucleotide(s) for performance of subsequent steps. Thus, in some aspects of the invention that recovery of active oligonucleotides refers to separation of active oligonucleotides from target biomolecule. In some preferred embodiments of the present invention active oligonucleotides may be recovered attendant to separation of the active from inactive oligonucleotide. In still other embodiments of the present invention, recovery requires additional steps.

Thereafter, active oligonucleotides may be characterized, such as by microanalytical characterization or standard nucleic acid sequencing. In some preferred embodiments of the present invention separation, recovery, and characterization are accomplished by the use of microanalytical resolution technologies combined with microanalytical characterization technologies, performed individually or integrated such as in "on-line" systems for maximum efficiency and conservation of material.

The microanalytical technique mass spectrometry (MS) may be effectively used to characterize

WO 93/05182

PCT/US92/07489

- 24 -

oligonucleotides. MS has been successfully applied to peptides. For example, Hunt, et al., *Science*, 1992, 255, 1261 and 1264 successfully identified the sequences of peptides (with theoretical complexity of 20^9) selected for binding (intracellularly) to MHC receptor molecules. After recovery and crude purification away from contaminating cellular components, the preferred peptide-MHC complexes (>200) were dissociated and the peptides resolved by microcapillary HPLC on-line to electrospray ionization tandem quadrupole FAB-MS, which identified the sequences of eight of the peptides present in only sub-pmole amounts.

MS can also be applied to both fully and partially resolved oligonucleotides. Furthermore, new non-destructive volatilization procedures now allow for MS application to biopolymers and analogs. For example, electrospray ionization (Weinberger, *Amer. Lab.* 1992, 54; and laser desorption, (Romano and Levis, *J. Amer. Chem. Soc.*, 1991, 113, 9665.

In other preferred embodiments of the present invention oligonucleotides are characterized by amplification and sequencing. Thus, in accordance with the present invention, a polynucleotide tail such as polyA is added to the 3' end of the highest specific activity selected oligonucleotide(s) to form a first strand. The term polyA is used to refer herein to the addition of a riboadenosine (to tail an RNA molecule) or deoxyadenosine (to tail a DNA molecule) and may be added via terminal deoxynucleotidyl transferase (TdT) for DNA or polyrA polymerase for RNA. Other methods of providing polynucleotide tails known to those skilled in the art are also encompassed herein. A first chimeric primer is hybridized to the first strand. The first chimeric primer is comprised of a 5' known sequence and a 3' polynucleotide portion complementary to the polynucleotide tail of the first strand. Thus, in the present example the first chimeric primer is comprised of a known sequence and a 3' polydT portion. The 3' polynucleotide portion is

WO 93/05182

PCT/US92/07489

- 25 -

preferably approximately from about 12 to about 16 nucleotides, and most preferably 15 nucleotides in length in order to optimize hybridization of the primer to the polynucleotide region of the first strand at lower temperatures. The 5' known sequence is preferably approximately 10 to about 15 nucleotides in length, and most preferably 12 nucleotides in length. The 5' known sequence is preferably also comprised of a high GC content that together with the 3' polynucleotide region allows for stringent binding at elevated temperatures. Thus, at higher temperatures required for PCR, there should be no cross-priming of the polynucleotide tails. In still further preferred embodiments of the present invention, the 5' region of the first chimeric primer may provide for one or more unique restriction sites. Such restriction sites may be useful for example, in forced cloning. Furthermore, the unique sequence serves a book keeping purpose in order to discriminate the sense from the antisense sequence in final sequencing. In yet further embodiments of the invention the first chimeric primer provides for mechanisms whereby the primer may be excised from the oligonucleotide of interest. For example, the first chimeric primer may incorporate a class IIS restriction endonuclease site. Class IIS restriction endonucleases ("shifters") cleave double stranded DNA at a precise number of nucleotides from the recognition site, regardless of the sequence of those nucleotides. For example, FokI cleaves double stranded DNA thirteen nucleotides from its recognition site, thereby removing the region downstream from the oligonucleotide of interest.

In still more preferred embodiments of the present invention a binding "handle" may be provided as a reactive group incorporated into the first chimeric primer. For example, a biotin moiety may be incorporated during synthesis at the 5' end of the first chimeric primer. Other binding "handles" will be apparent to one skilled in the art given the present disclosure.

WO 93/05182

PCT/US92/07489

- 26 -

In certain embodiments of the present invention, the first chimeric primer may be captured on a solid support. For example, the primer may be streptavidin captured using an incorporated biotin binding "handle". In
5 other embodiments of the present invention the primer may be covalently attached to microtitre plates such as by modifications of the method described by Mitsuhashi, et al., *Nature*, 1992, 357, 519. Such capture may facilitate washing during the preparation of the flanking "primer
10 sites" flanking either end of the oligonucleotide of interest.

Polymerase such as Taq I polymerase in the presence of an excess of all four nucleotides may be used to form cDNA complementary to the first strand using the first
15 chimeric primer. The cDNA may be further extended at its 3' end with a polynucleotide tail such as polydA by addition of excess nucleotide in the presence of an appropriate enzyme such as TdT. For example, the cDNA may be further extended at its 3' end with a polydA by the
20 addition of dATP in the presence of TdT. The first strand and the cDNA strand may subsequently be separated by heating.

A second chimeric primer may then be hybridized to the cDNA strand at a lower hybridization temperature,
25 resulting in 3' recessed ends on both strands. The second chimeric primer, like the first, is comprised of a 5' known sequence and a 3' polynucleotide portion which is complementary to the polynucleotide tail of the cDNA. Thus, in the present example, the second chimeric primer
30 has a 3' polydT portion which is complementary to the polyA tail of the cDNA. The 3' polynucleotide portion is preferably approximately from about 12 to about 16 nucleotides, and most preferably 15 nucleotides in length and the 5' known sequence is preferably approximately 10 to
35 about 17 nucleotides in length, and most preferably 13 or 15 nucleotides in length. The 5' known sequence of the second chimeric primer is also comprised of a high GC

WO 93/05182

PCT/US92/07489

- 27 -

content that together with the 3' polynucleotide region allows for stringent binding at elevated temperatures and may provide for a unique restriction site. The second chimeric primer also provides for mechanisms whereby the primer may be excised from the oligonucleotide of interest. For example, the second chimeric primer may incorporate a riboU at the 3' terminus. The ribophosphate diester bond may be cleaved by selective specific base (-OH) hydrolysis or RNase treatment, thus excising the primer and any upstream regions from the region downstream from the riboU site.

The recessed ends are filled in by the addition of a polymerase such as Taq I and an excess of all four nucleotides. Thus, using recessed ends as primers and the overhangs as templates, complementary strands are formed. The resulting fully complementary and fully duplex strands are separated by heating and polymerase chain reaction is performed to amplify the oligonucleotides. Polymerase chain reaction procedures are well known in the art. Ausubel, et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, 1989. The first and second chimeric primers may effectively serve as PCR primers.

The amplified oligonucleotides may be force cloned using the primer sequence unique restriction sites or PCR product single base overhang cloned and sequenced by procedures known in the art. Alternatively, in some embodiments of the present invention the oligonucleotide of interest may be excised from the upstream and downstream flanking regions, re-assayed for selective binding, recovered and characterized. For example, by relying upon mechanisms incorporated within primers having the sequences GGATG(dT)₁₃ (SEQ ID NO: 1; first chimeric primer) and CGC TGG ATC CGC (dT)₁₄ rU (SEQ ID NO: 2; second chimeric primer) the oligonucleotide may be restricted with FokI, the ribophosphate diester bonds may be selectively cleaved by hydrolysis or treatment with RNase to excise the original random oligonucleotide of interest from the flanking

WO 93/05182

PCT/US92/07489

- 28 -

regions added herein to facilitate amplification of the oligonucleotides.

The oligonucleotides of the present invention can be used in diagnostics, therapeutics and as research reagents. For therapeutic uses, an effective amount of the oligonucleotide is administered to an animal, especially a human, suffering from a disorder effected by a biomolecule. Said biomolecule may be derived from an infectious agent such as a herpesvirus. Further, said biomolecule may be derived from a noninfectious agent of, for example, genetic origin. Effective amounts of therapeutic agents of the present invention, may be applied topically, intralesionally, orally, transdermally, intravenously or intramuscularly, as appropriate for the particular disorder to be treated. One skilled in the art would be apprised of the method most effective for any given disorder. Use of pharmacologically acceptable carriers is also preferred for some embodiments. The present invention is also useful in diagnostics and in research, as it is may be easily adapted to suit a range of assays.

The following examples are illustrative, but not limiting of the present invention.

EXAMPLE 1

Synthesis of DNA Oligonucleotides

Unmodified DNA oligonucleotides were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. β -cyanoethyldiisopropyl phosphoramidites may be purchased from Applied Biosystems (Foster City, CA).

Example 2

Synthesis of RNA Oligonucleotides

Unmodified RNA oligonucleotides having random base sequences were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using modified

WO 93/05182

PCT/US92/07489

- 29 -

standard phosphoramidite chemistry synthesis with oxidation by iodine. The standard synthesis was modified by increasing the wait step after the pulse delivery of tetrazole to 900 seconds. β -cyanoethyldiisopropyl

5 phosphoramidites were purchased from Applied Biosystems (Foster City, CA). The bases were deprotected by incubation in methanolic ammonia overnight. Following base deprotection, the oligonucleotides were dried *in vacuo*. The t-butyldimethylsilyl protecting the 2' hydroxyl was

10 removed by incubating the oligonucleotide in 1M tetrabutylammoniumfluoride in tetrahydrofuran overnight. The RNA oligonucleotides were further purified on C₁₈ Sep-Pak cartridges (Waters, Division of Millipore Corp., Milford, MA) and ethanol precipitated.

15 Example 3

Synthesis of Phosphorothioate Oligonucleotides

Phosphorothioate oligonucleotides represent a class of oligonucleotide analog that is substantially nuclease resistant. Phosphorothioate RNA oligonucleotides

20 and phosphorothioate DNA oligonucleotides were synthesized according to the procedure set forth in Examples 1 and 2 respectively, replacing the standard oxidation bottle by a 0.2M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for stepwise thiation of phosphite linkages.

25 The thiation cycle wait step was increased to 68 seconds and is followed by the capping step.

Example 4

Synthesis of 2'-O-alkyl Phosphorothioate Oligonucleotides

2'-O-methyl phosphorothioate oligonucleotides

30 were synthesized according to the procedures set forth in Example 3 substituting 2'-O-methyl β -cyanoethyldiisopropyl phosphoramidites (Chemgenes, Needham, MA) for standard phosphoramidites and increasing the wait cycle after the pulse delivery of tetrazole and base to 360 seconds.

35 Similarly, 2'-O-propyl, 2'-O-phenyl and 2'-O-nonyl

WO 93/05182

PCT/US92/07489

- 30 -

phosphorothioate oligonucleotides may be prepared by slight modifications of this procedure.

Example 5

Preparation of Pyrene Oligonucleotide Analogs

- 5 Oligonucleotides were prepared by incorporating 2' aminopentoxymadenosine at desired sites. The oligonucleotides were dissolved in 0.2M NaHCO₃ buffer and treated with 50 fold excess of N-hydroxysuccinimide ester of pyrene-1-butyric acid dissolved in dimethylformamide.
- 10 The resultant mixture is incubated at 37°C for 4-5 hours and the conjugate is purified by reverse phase HPLC followed by desalting in a G-25 Sephadex column.

Example 6

Synthesis of Oligonucleotide Pools Having Randomized

15 Positions

- Four columns of the DNA synthesizer were packed with a mixture containing an equal amount of adenosine(A)-, cytidine(C)-, guanosine(G)- and uracil(U)-controlled pore glass (CPG, Chemgenes, Needham, MA). At coupling steps
- 20 where a given nucleotide base was desired, the defined phosphoramidite was delivered to each column. At each "random" coupling step, an equimolar mixture of all four phosphoramidites was delivered to each column.

Example 7

25 Preparation of Radiolabeled Groups

- Oligonucleotide groups prepared in accordance with Example 1 through 6 may be radiolabeled using [γ -³²P] ATP and T4 polynucleotide kinase as described in Maniatis, et al. "Molecular Cloning: A Laboratory Manual" (Cold
- 30 Spring Harbor, NY).

WO 93/05182

PCT/US92/07489

- 31 -

Example 8**Preparation of Oligonucleotide Group comprising Nucleotide Analogs.**

Oligonucleotide groups are prepared in accordance with Example 1 and 6 incorporating one or more of the nucleoside analogs 2'-O-nonyl adenosine, N6-imidazolylpropyl guanosine, 2'-O-aminopentyl cytidine, 2'-O-pentyl-adenosine, 2'-O-pentyl-guanosine, 2'-O-pentyl-cytidine, 3'-terminal 2'-O-methyl uridine and 6-amino-2-hydroxymethyl-1-hexanol. The nucleosides, 2'-O-nonyl adenosine, N6-imidazolylpropyl guanosine, 2'-O-aminopentyl cytidine, 2'-O-pentyl-adenosine, 2'-O-pentyl-guanosine, 2'-O-pentyl-cytidine, 3'-terminal 2'-O-methyl uridine were prepared by modification of the methods described in PCT US91/00243 filed 1/11/91. 6-amino-2-hydroxymethyl-1-hexanol is available commercially. The nucleosides are modified to provide the corresponding phosphoramidite by methods known to those skilled in the art.

EXAMPLE 9**20 Gel Shift assay of Random DNA Oligonucleotide Binding to ras RNA Target and Enzymatic Amplification of Active Oligonucleotides**

The ras 47-mer stem/loop RNA is enzymatically synthesized, ³²P end-labeled according to standard procedures, and gel-purified. The ras target is incubated at a concentration of approximately 10-50pM with DNA oligonucleotide pools synthesized in accordance with the method described in Examples 1 and 6 at concentrations of 1, 5, 10, 50 and 100 μM in a buffer consisting of 100mM NaCl and 10mM MgCl₂. The hybridization is carried out for four hours at 37°C, followed by electrophoresis separation of bound vs. unbound material on a 20% polyacrylamide gel in Tris-Borate buffer (TBE) plus 50mM NaCl run at 25W for four hours. The gel is dried and the radioactive bands are visualized on a phosphorimager (Molecular Dynamics). The ras stem/loop target alone will be the lowest band visible

WO 93/05182

PCT/US92/07489

- 32 -

on the gel (highest mobility). As this target binds oligonucleotide (non-radioactive), the mobility of the ras target will decrease, shifting the band to a higher position on the gel (complex). The bound complex is excised from the gel with a sterile razor blade. The oligonucleotides (ras RNA and bound oligonucleotide(s)) are recovered by the crush and soak method. The ras RNA and binding selected oligonucleotide(s) are separated by size using HPLC procedures and the fraction(s) containing the binding selected oligonucleotides collected. The recovered oligonucleotides are amplified in accordance with the following steps:

(1) Poly dA tailing of recovered oligonucleotides to form a first strand

Tailing of recovered oligonucleotides is carried out in a microtitre well using 5-50 units terminal deoxynucleotide transferase (Boehringer Mannheim Biochemicals) according to manufacturer's instructions [2 hours, 37°C in tailing buffer (supplied with enzyme) plus 1.5 mM CoCl₂ and 100 nmoles dATP]. Reaction volume is 20 µl.

(2) Preparation of a first chimeric primer

A first chimeric primer is synthesized by automated chemical synthesis. At the 5' end is a known sequence incorporating a ribonuclease restriction site for FokI and a biotin moiety at the 5' termini. At the 3' end is a 13 nucleotide polydT stretch. This primer is added at micromolar concentrations to the reaction mixture in a buffer consisting of 10mM Tris-HCl, pH 7.5, 150mM NaCl and allowed to hybridized to the first strand.

(3) Capture of the first chimeric primer with 5'-biotin-streptavidin

A microtitre well is coated with 50µg/ml streptavidin in sodium carbonate, pH 9.25 for 3 hours at 37°C. Alternatively, commercially available streptavidin ready-coated microtitre plates (Labsystems, Marlboro, MA) can be used. Nonspecific binding sites are blocked with

WO 93/05182

PCT/US92/07489

- 33 -

0.3% bovine serum albumin in 10mM Tris-HCl, pH 8.0, 150mM NaCl at 37°C for 3 hours. The first chimeric primer/oligonucleotide duplex is then bound to the streptavidin-coated plates by incubating for 1 hour at 37°C
5 in 100mM Tris-HCl, 150 mM NaCl, pH 8.0.

(4) Polymerase copy of first strand to form double-stranded duplex:

To the microtitre well is added 0.4 units Taq polymerase (Promega), micromolar amounts of each dNTP, and
10 1x polymerase buffer (Promega) to a final volume of 50 µl. The reaction is carried out for 3 to 12 hours at room temperature. Well are washed six times in wash buffer.

(5) Poly-dA tailing of cDNA of duplex

Tailing of the cDNA is carried out in a
15 microtitre well using 5-50 units terminal deoxynucleotide transferase (Boehringer Mannheim Biochemicals) according to manufacturer's instructions [2 hours, 37°C in tailing buffer (supplied with enzyme) plus 1.5 mM CoCl₂ and 100 nmoles dATP]. Well is washed 6 times with 200 µl of wash
20 buffer.

(6) Separation of cDNA and oligonucleotide

The microtitre plate is heated to 85°C to melt the duplex and the supernatant is removed. The well is washed six times with 200 µl wash buffer.

25 (7) Preparation of a second chimeric primer

A second chimeric primer is synthesized by automated chemical synthesis. At the 5' end is a known sequence incorporating a ribonuclease restriction site for BamH1. At the 3' end is a 14 nucleotide polydT stretch
30 ending in a riboU at its termini. This primer is added at micromolar concentrations to the reaction mixture in a buffer consisting of 10mM Tris-HCl, pH 7.5, 150mM NaCl and allowed to hybridize to the first strand.

(8) Filling in recessed ends to form a duplex

35 To the microtitre well is added 0.4 units Taq polymerase (Promega), micromolar amounts of each dNTP, and 1x polymerase buffer (Promega) to a final volume of 50 µl.

- 34 -

The reaction is carried out for 3 to 12 hours at room temperature. Wells are washed six times in wash buffer. The microtitre plate is heated to $\geq 85^{\circ}\text{C}$ to melt the duplex.

- 5 (9) PCR Amplification of Oligonucleotides
PCR amplification is performed using Taq polymerase according to standard methods (Frederick M. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, 1989) using first and second chimeric
10 primers from (2) and (7) as PCR primers.

(10) Excising oligonucleotide from upstream and downstream flanking regions

- Amplified oligonucleotides are excised from flanking regions by cleavage with FokI in accordance with
15 suppliers recommendations (Boehringer Mannheim). After FokI restriction and melting apart of the restricted sense and antisense fragments, the reaction mixture was treated with mild base to cleave the upstream primer region from the sense strand by selective hydrolysis of the
20 ribophosphate diester linkage between the 3'-riboU of the primer and the 5' region of the oligonucleotide of interest.

- (11) The selection steps and amplification steps are repeated until only one, or at most only a few, unique
25 oligonucleotide sequences reproducible are recovered from "round to round".

- (12) Sequencing of amplified oligonucleotide(s):
The sequence is determined using the standard Sanger ddNTP method and Sequenase enzyme (Pharmacia, Inc.)
30 (Frederick M. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, 1989). Sequencing can be done with one, two, three, or all four ddNTPs, depending on the extent of sequence bias, or if exact sequence is desired.

WO 93/05182

PCT/US92/07489

- 35 -

EXAMPLE 10

**Gel Shift assay of Random 2'-O-Methyl Oligonucleotide
Binding to ras RNA Target and Microanalytical
Characterization**

5 The ras 47-mer stem/loop RNA is enzymatically
synthesized, ³²P end-labeled according to standard
procedures, and gel-purified. The ras target is incubated
at a concentration of approximately 10-50pM with random 2'-
O-methyl oligonucleotide pools synthesized in accordance
10 with the method described in Examples 4 and 6 at
concentrations of 1, 5, 10, 50 and 100 μM in a buffer
consisting of 100mM NaCl and 10mM MgCl₂. The hybridization
is carried out for four hours at 37°C, followed by
electrophoresis separation of bound vs. unbound material on
15 a 20% polyacrylamide gel in Tris-Borate buffer (TBE) plus
50mM NaCl run at 25W for four hours. The gel is dried and
the radioactive bands are visualized on a phosphorimager
(Molecular Dynamics). The ras stem/loop target alone will
be the lowest band visible on the gel (highest mobility).
20 As this target binds oligonucleotide (non-radioactive), the
mobility of the ras target will decrease, shifting the band
to a higher position on the gel (complex). The bound
complex is excised from the gel with a sterile razor blade.
The oligonucleotides (ras RNA and bound oligonucleotide(s))
25 are recovered by crush and soak method or by
electroelution. The ras RNA and binding selected
oligonucleotide(s) are separated by RNAase degradation
which selectively degrades the ras RNA to mononucleotides,
leaving the selected, RNase resistant 2'-O-methyl
30 oligonucleotide(s) intact. The selected oligonucleotides
are identified by the use of microbore HPLC and mass
spectrometry to determine the bound oligonucleotide
sequences. To facilitate MS sequencing determination, the
recovered 2'-O-methyl oligonucleotide(s) can be fragmented
35 by prolonged treatment (compared to RNA or DNA) with any of
a number of available nucleases; sequencing of shorter
fragments by MS is easier and the sequence of the parent

WO 93/05182

PCT/US92/07489

- 36 -

oligonucleotide can be reconstructed from overlapping sequences of the fragments.

EXAMPLE 11

Gel Shift Assay of Random Pyrene Oligonucleotide Sets

5 Binding to HIV TAR Element

The HIV TAR element is a structured RNA found on the 5'-end of all HIV transcripts. A gel shift is used to analyze the binding of oligonucleotides of a random oligonucleotide pool prepared in accordance with Examples 5 and 6, each oligonucleotide pool containing a pyrene analog to the HIV TAR element. The target RNA has a three base bulge that is required for binding of the transcriptional activation protein tat. The assay uses a very low concentration of pools. Binding of molecules from the pool to the target results in a slower mobility complex. Recovery of the bound oligonucleotide(s) and identification of sequences can be accomplished as described in Example 10.

EXAMPLE 12

20 Random 2'-O-Methyl Oligonucleotide Binding to ras RNA using Continuous Flow Mass Transport Methodology to Effect Stringent Binding Selection

The ras 47-mer stem/loop RNA is enzymatically synthesized, may be ³²P end-labeled according to standard procedures, and gel-purified.

A fast protein liquid chromatography (FPLC, Pharmacia) system is calibrated to separated bound from unbound oligonucleotides. The column used is a Superous 12 HR 10/30, fractionation MW range of 10³ - 3X10⁵ (for proteins), >40,000 theoretical plates/m, 1.0x30cm, with ≤ 6-30mL/min flow rate. Starting conditions are 10-50mM TE buffer, pH 7.0, 1mM magnesium chloride and 100mM sodium chloride.

Calibration 2'-O-methyl oligonucleotides having the sequences UGCCCACAC (SEQ ID NO:3), UGCCCACAU (SEQ ID

WO 93/05182

PCT/US92/07489

- 37 -

NO:4), UUGCUCACAC (SEQ ID NO:5), CUGCCCACAU (SEQ ID NO:6),
and CUGUUUACAU (SEQ ID NO:7) are prepared and radiolabeled
using polynucleotide kinase and ³²P-ATP. Alternatively,
rather than label the oligonucleotides, the target
5 molecule, ras RNA may be ³²P labeled or both oligonucleotide
and target may be labeled. These calibration
oligonucleotides should be of the same length as the
randomized oligonucleotides to be tested and are of varying
degrees of sequence complementarity to the target molecule.
10 The FPLC column is calibrated before antisense
selection from combinatorial pools by running the
calibration ³²P labeled-2'-O-methyl oligonucleotides;
individually (for unbound species retention times (RT)) and
as a mixture of calibration 2'-O-methyl oligonucleotides
15 which has been incubated with ras RNA to form any possible
hybridization complexes (for retention times of bound and
differential rate dissociated species). The mixture is
then loaded on the column and run to provide an elution
profile. Alternatively, the calibration oligonucleotides
20 may be added to the column as a mixture, followed by the
addition of the ras RNA. As the ras RNA should flow faster
than the oligonucleotides, it should flow past the
oligonucleotides. This continuous flow combining binding
and resolution may allow for better separation and recovery
25 because the mass action bulk equilibrium starting point of
pre-binding is to some extent avoided. The effect of
adding a weak, nonspecific binder of oligonucleotides in
mass excess in the mobile phase can similarly be assessed.
Following calibration, either the random
30 oligonucleotide pool is loaded onto the column followed by
the ras RNA or the pool and ras RNA are pre-incubated
(37°C, 1-4 hours) prior to loading on the column. Bound
oligonucleotide/ras RNA complex(es) are dissociated using
stepwise or gradient low salt and/or increased temperature.
35 and the oligonucleotides are recovered by RNase treatment
to selectively degrade the ras RNA. The selected 2'-O-
methyl oligonucleotides are characterized by microbore HPLC

WO 93/05182

PCT/US92/07489

- 38 -

(Smart Systems from Pharmacia). Complete and limited fragmentation of the recovered 2'-O-methyl oligonucleotides can be accomplished by appropriate base and nuclease treatment to facilitate sequence reconstruction in
5 comparison to pre-calibrated retention times of standard mono, di, and tri 2'-O-methyl standards.

EXAMPLE 13**FPLC resolution of Random RNA Oligonucleotide Binding to ras RNA**

10 The ras 47-mer stem/loop RNA is enzymatically synthesized, is biotin-labeled according to standard procedures, and gel-purified. Calibration oligonucleotides were prepared and FPLC system calibrated as described in Example 13. An RNA random oligonucleotide pool was
15 prepared in accordance with Examples 2 and 6 and the FPLC binding assay was performed as described in Example 13. The RNA-oligonucleotide(s) bound complex(es) were recovered using biotin-streptavidin capture of the biotinylated ras RNA. The bound oligonucleotide(s)/ras RNA complex(es) are
20 dissociated using low salt and/or increased temperature and the selected oligonucleotide(s) recovered from the supernatant. The oligonucleotide was amplified in accordance with Example 10.

EXAMPLE 14**25 In Vitro Evolution of Longer Oligonucleotides of Greater Complexity for Enhanced Binding Affinity and Specificity**

A "winner" sequence is determined in accordance with one of the Examples 9-13. The "winner" sequence is designated a cassette for purposes of the invention, i.e.
30 an oligonucleotide sequence determined by an initial application of methods of the invention.

In subsequent application of methods of the invention a randomized oligonucleotide pool is prepared in accordance with Example 1 comprising the previously
35 determined cassette and at least one randomized flanking

WO 93/05182

PCT/US92/07489

- 39 -

region. Selection for activity is performed and the oligonucleotide characterized as described in Examples 10-14. These steps can be performed iteratively. Thus, the final sequence may subsequently be used as a cassette in order to expand upon the known desired sequence to optimize selective activity.

EXAMPLE 15**Identification of Oligonucleotide Sequence Using Streptavidin Capture of Biotinylated Target**

10 A target oligonucleotide (0.2 μ M) having the sequence 3'dBAB AGA CGT CTT GCG 5' (SEQ ID NO:8) wherein B is biotin, was incubated for 30 minutes at room temperature with a radiolabeled 2'-O-methyl oligonucleotide sequence randomized pool (10 μ M) having the sequence NNNNCNCNN
15 wherein N is any of adenine, cytosine, thymine or guanine. The target oligonucleotide was captured on streptavidin-coated magnetic beads (Promega), the beads were washed, and supernatant removed. The bead-containing sample was run on polyacrylamide gel to determine the sample having the
20 highest binding. The binding selective steps were repeated until a winner sequence was identified. Enrichment in each step (measured by radioactivity) was 200-1000 fold. Confirmation of the sequence of the final, best binding oligonucleotide was provided by complete blocking of
25 binding of radioactivity by 0.1 μ M of unlabeled target complementary to the sequence competitor.

EXAMPLE 16**Identification of a Protein Target**

A group of oligonucleotides having the sequence
30 NNNNNNNN wherein N is any one of adenine, guanine, thymidine or cytosine is prepared in accordance with Examples 3 and 6. The group is labeled using [γ -³²P] ATP and T4 polynucleotide kinase.

In individual wells of a 96-well nitrocellulose
35 filter manifold, the following proteins are incubated in a

WO 93/05182

PCT/US92/07489

- 40 -

solution of phosphate buffered saline: plasminogen activator A₂, tumor necrosis factor α , tumor necrosis factor β and gp120. Phosphate buffered saline only is added to a control well. The filter is washed. An aliquot of the
5 labeled group of oligonucleotides is added to each well and incubated at room temperature for 10 minutes. The filter is washed and the counts in each well over background are counted to determine whether binding of the oligonucleotide to the protein occurred.

WO 93/05182

PCT/US92/07489

- 42 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGATGTTTTT TTTTTTTT

18

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGCTGGATCC GCTTTTTTTT TTTTTTU

27

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

UUGCCCACAC

10

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

UUGCCCACAU

10

WO 93/05182

PCT/US92/07489

- 43 -

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

UUGCUCACAC

10

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CUGCCCACAU

10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CUGUUUACAU

10

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

WO 93/05182

PCT/US92/07489

- 44 -

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAGACGTCTT GCG

13

WO 93/05182

PCT/US92/07489

- 45 -

CLAIMS

What is claimed is:

1. A method of determining an oligonucleotide having specific activity for a target biomolecule
5 comprising the steps of:
 - (a) preparing a set of randomized oligonucleotides;
 - (b) subfractionating the set of randomized oligonucleotides to provide subfractions of said
10 oligonucleotides;
 - (c) assaying the subfractions of randomized oligonucleotides for activity against a target biomolecule;
 - (d) selecting the subfraction having the highest activity;
 - 15 (e) assaying the oligonucleotides of the selected subfraction for activity against a target biomolecule;
 - (f) separating active from inactive oligonucleotides;
 - 20 (g) recovering said active oligonucleotides;
 - (h) extending a polyA on said active oligonucleotide in a 3' direction to form a first strand;
 - (i) hybridizing said first strand to a first chimeric primer having a 5' known sequence and a 3' polydT
25 portion.
 - (j) forming a cDNA strand, complementary to the active oligonucleotide, using the first chimeric primer;
 - (k) extending said cDNA formed in (j) in a 3' direction by the addition of polyA;
 - 30 (l) separating said oligonucleotide and cDNA strand;
 - (m) hybridizing the polyA portion of said cDNA strand to a second chimeric primer having a 5' known sequence and a 3' polydT portion;

WO 93/05182

PCT/US92/07489

- 46 -

- (n) filling in the recessed 3' ends to form two complementary strands;
- (o) separating the strands;
- (p) amplifying the strands formed in (m) using
- 5 the first and second chimeric primers by polymerase chain reaction;
- (q) excising active oligonucleotide from flanking regions;
- (r) recovering active oligonucleotide; and
- 10 (s) performing steps (b) through (r) iteratively to determine an active oligonucleotide.

2. The method of claim 1 further comprising determining the nucleic acid sequence of the active oligonucleotide.

15 3. The method of claim 1 wherein the biomolecule is a DNA molecule.

4. The method of claim 1 wherein the biomolecule is an RNA molecule.

5. The method of claim 1 wherein the

20 biomolecule is polypeptide.

6. The method of claim 1 wherein the biomolecule is a glycoprotein.

7. The method of claim 1 wherein the biomolecule is a carbohydrate.

25 8. The method of claim 1 wherein the set of randomized oligonucleotides is detectably labeled.

9. The method of claim 1 wherein the set of randomized oligonucleotides is conformationally constrained.

WO 93/05182

PCT/US92/07489

- 47 -

10. A method of determining an oligonucleotide having specific activity for a target biomolecule comprising the steps of:

- (a) preparing a set of randomized
5 oligonucleotides;
- (b) assaying the set of randomized oligonucleotides for activity against a target biomolecule;
- (c) separating active from inactive oligonucleotides;
- 10 (d) recovering active oligonucleotide;
- (e) extending a polyA on said active oligonucleotide in a 3' direction to form a first strand;
- (f) hybridizing said first strand to a first
15 chimeric primer having a 5' known sequence and a 3' polydT portion.
- (g) forming a cDNA strand, complementary to active oligonucleotide, using the first chimeric primer;
- (h) extending said cDNA formed in (g) in a 3' direction by the addition of polyA;
- 20 (i) separating said oligonucleotide and cDNA strand;
- (j) hybridizing the polyA portion of said cDNA strand to a second chimeric primer having a 5' known sequence and a 3' polydT portion;
- 25 (k) filling in the recessed 3' ends to form two complementary strands;
- (l) separating the strands;
- (m) amplifying the strands formed in (k) using the first and second chimeric primers by polymerase chain
30 reaction;
- (n) excising active oligonucleotide;
- (o) recovering active oligonucleotide; and
- (p) performing steps (b) through (o) iteratively to determine an oligonucleotide having specific activity
35 for a target biomolecule.

WO 93/05182

PCT/US92/07489

- 48 -

11. The method of claim 10 further comprising determining the nucleic acid sequence of the active oligonucleotide.

12. The method of claim 10 wherein the
5 biomolecule is a DNA molecule.

13. The method of claim 10 wherein the biomolecule is an RNA molecule.

14. The method of claim 10 wherein the biomolecule is polypeptide.

10 15. The method of claim 10 wherein the biomolecule is a glycoprotein.

16. The method of claim 10 wherein the biomolecule is a carbohydrate.

15 17. The method of claim 10 wherein the set of randomized oligonucleotides is detectably labeled.

18. The method of claim 10 wherein the set of randomized oligonucleotides is conformationally constrained.

19. A method for determining an oligonucleotide
20 having specific activity for a target biomolecule comprising the steps of:

(a) preparing a set of randomized oligonucleotides;

(b) subfractionating the set of randomized
25 oligonucleotides to provide subfractions of said oligonucleotides;

(c) assaying each of the subfractions of randomized oligonucleotides for activity against a target biomolecule;

WO 93/05182

PCT/US92/07489

- 49 -

- (d) selecting the subfraction having the highest activity;
- (e) assaying the oligonucleotides of the selected subfraction for activity against a target biomolecule;
- (f) separating active from inactive oligonucleotides;
- (g) recovering said active oligonucleotides;
- (h) amplifying the active oligonucleotides recovered in (d); and
- (i) determining the nucleic acid sequence of said amplified oligonucleotides.

20. The method of claim 19 wherein the biomolecule is a DNA molecule.

21. The method of claim 19 wherein the biomolecule is an RNA molecule.

22. The method of claim 19 wherein the biomolecule is polypeptide.

23. The method of claim 19 wherein the biomolecule is a glycoprotein.

24. The method of claim 19 wherein the biomolecule is a carbohydrate.

25. The method of claim 19 wherein the set of randomized oligonucleotides is detectably labeled.

26. The method of claim 19 wherein the set of randomized oligonucleotides is conformationally constrained.

WO 93/05182

PCT/US92/07489

- 50 -

27. A method of determining an oligonucleotide having specific activity for a target biomolecule comprising the steps of:

- (a) preparing a set of randomized
5 oligonucleotides;
- (b) assaying the set of randomized oligonucleotides for activity against a target biomolecule;
- (c) separating active from inactive oligonucleotides;
- 10 (d) recovering said active oligonucleotides;
- (e) amplifying the active oligonucleotides; and
- (f) determining the nucleic acid sequence of said amplified oligonucleotides.

28. The method of claim 27 wherein the
15 biomolecule is a DNA molecule.

29. The method of claim 27 wherein the biomolecule is an RNA molecule.

30. The method of claim 27 wherein the biomolecule is polypeptide.

20 31. The method of claim 27 wherein the biomolecule is a glycoprotein.

32. The method of claim 27 wherein the biomolecule is a carbohydrate.

25 33. The method of claim 27 wherein the set of randomized oligonucleotides is detectably labeled.

34. The method of claim 27 wherein the set of randomized oligonucleotides is conformationally constrained.

WO 93/05182

PCT/US92/07489

- 51 -

35. A method of amplifying oligonucleotides comprising the steps of:

- (a) extending a polyA on an oligonucleotide in a 3' direction to form a first strand;
- 5 (b) hybridizing said first strand to a first chimeric primer having a 5' known sequence and a 3' polydT portion.
- (c) forming a cDNA strand, complementary to the oligonucleotide, using the first chimeric primer;
- 10 (d) extending said cDNA formed in (c) in a 3' direction by the addition of polyA;
- (e) separating said oligonucleotide and cDNA strand;
- (f) hybridizing the polyA portion of said cDNA
- 15 strand to a second chimeric primer having a 5' known sequence and a 3' polydT portion;
- (g) filling in the recessed 3' ends to form two complementary strands;
- (h) separating the strands;
- 20 (i) amplifying the strands formed in (g) using the first and second chimeric primers by polymerase chain reaction.

36. The method of 35 wherein the known sequences of the first and second chimeric primers provide unique

25 restriction sites.

37. The method of claim 35 wherein the known sequence of the first chimeric primer contains a recognition site for a class IIS restriction endonuclease and is of an appropriate length to result in cleavage of

30 the entire primer upon treatment with said restriction endonuclease and the second chimeric primer has a riboU as its 3' residue further comprising:

- (j) treating the polymerase chain reaction products with a class IIS restriction endonuclease and

WO 93/05182

PCT/US92/07489

- 52 -

cleaving the ribophosphate diester linkage to excise the oligonucleotide.

38. A method of determining an oligonucleotide having specific activity for a target biomolecule comprising the steps of:
- (a) preparing a set of randomized oligonucleotides;
 - (b) assaying the set of randomized oligonucleotides for activity against a target biomolecule;
 - 10 (c) separating active from inactive oligonucleotides;
 - (d) recovering said active oligonucleotides;
 - (e) characterizing the recovered oligonucleotides to provide an oligonucleotide cassette;
 - 15 (f) preparing a set of oligonucleotides comprising a cassette and at least one flanking region of randomized positions;
 - (g) assaying the set of oligonucleotides for activity against a target biomolecule;
 - 20 (h) separating active from inactive oligonucleotides;
 - (i) recovering said active oligonucleotides;
 - (j) characterizing the recovered oligonucleotides to provide an oligonucleotide cassette;
 - 25 and
 - (k) performing steps (f) through (j) iteratively to determine an oligonucleotide having specific activity for a target biomolecule.

39. The method of claim 38 wherein the active and inactive oligonucleotides are separated by microanalytical techniques.

40. The method of claim 38 wherein the recovered oligonucleotides are characterized by microanalytical structural determination or by amplifying the active

WO 93/05182

PCT/US92/07489

- 53 -

oligonucleotides and determining the nucleic acid sequence of said amplified oligonucleotides.

41. A method for determining an oligonucleotide having specific activity for a target biomolecule comprising the steps of:
- (a) preparing a set of randomized oligonucleotides;
 - (b) subfractionating the set of randomized oligonucleotides to provide subfractions of said oligonucleotides;
 - (c) assaying each of the subfractions of randomized oligonucleotides for activity against a target biomolecule;
 - (d) selecting the subfraction having the highest activity;
 - (e) assaying the oligonucleotides of the selected subfraction for activity against a target biomolecule;
 - (f) separating active from inactive oligonucleotides;
 - (g) recovering said active oligonucleotides; and
 - (h) characterizing the recovered oligonucleotides by microanalytical structural determination.

42. The method of claim 41 wherein said microanalytical structural determination is mass spectrometry.

43. The method of claim 41 wherein the biomolecule is a DNA molecule.

44. The method of claim 41 wherein the biomolecule is an RNA molecule.

WO 93/05182

PCT/US92/07489

- 54 -

45. The method of claim 41 wherein the biomolecule is polypeptide.

46. The method of claim 41 wherein the biomolecule is a glycoprotein.

5 47. The method of claim 41 wherein the biomolecule is a carbohydrate.

48. The method of claim 41 wherein the set of randomized oligonucleotides is detectably labeled.

10 49. The method of claim 41 wherein the set of randomized oligonucleotides is conformationally constrained.

50. A method of determining an oligonucleotide having specific activity for a target biomolecule comprising the steps of:

- 15 (a) preparing a set of randomized oligonucleotides;
- (b) assaying the set of randomized oligonucleotides for activity against a target biomolecule;
- (c) separating active from inactive
- 20 oligonucleotides;
- (d) recovering said active oligonucleotides; and
- (e) characterizing the recovered oligonucleotides by microanalytical structural determination.

25 51. The method of claim 50 wherein said microanalytical structural determination is mass spectrometry.

52. The method of claim 50 wherein the biomolecule is a DNA molecule.

WO 93/05182

PCT/US92/07489

- 56 -

65. An oligonucleotide identified in accordance with the method of claim 50.

66. The composition of claim 59 in a pharmaceutically acceptable carrier.

5 67. The composition of claim 60 in a pharmaceutically acceptable carrier.

68. The composition of claim 61 in a pharmaceutically acceptable carrier.

69. The composition of claim 62 in a
10 pharmaceutically acceptable carrier.

70. The composition of claim 63 in a pharmaceutically acceptable carrier.

71. The composition of claim 64 in a pharmaceutically acceptable carrier.

15 72. The composition of claim 65 in a pharmaceutically acceptable carrier.

73. A method for treating a disease caused by an infectious agent comprising administering to an animal suspected of having the disease an oligonucleotide
20 identified in accordance with claim 1.

74. The method of claim 73 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or
25 influenza virus.

75. A method for treating a disease caused by an infectious agent comprising administering to an animal

WO 93/05182

PCT/US92/07489

- 57 -

suspected of having the disease an oligonucleotide identified in accordance with claim 10.

76. The method of claim 75 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or influenza virus.

77. A method for treating a disease caused by an infectious agent comprising administering to an animal suspected of having the disease an oligonucleotide identified in accordance with claim 19.

78. The method of claim 77 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or influenza virus.

79. A method for treating a disease caused by an infectious agent comprising administering to an animal suspected of having the disease an oligonucleotide identified in accordance with claim 27.

80. The method of claim 79 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or influenza virus.

81. A method for treating a disease caused by an infectious agent comprising administering to an animal suspected of having the disease an oligonucleotide identified in accordance with claim 38.

WO 93/05182

PCT/US92/07489

- 58 -

82. The method of claim 81 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or
5 influenza virus.

83. A method for treating a disease caused by an infectious agent comprising administering to an animal suspected of having the disease an oligonucleotide identified in accordance with claim 41.

10 84. The method of claim 83 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or influenza virus.

15 85. A method for treating a disease caused by an infectious agent comprising administering to an animal suspected of having the disease an oligonucleotide identified in accordance with claim 50.

20 86. The method of claim 85 wherein the infectious agent is Candida, papillomavirus, cytomegalovirus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, or influenza virus.

25 87. A method of treating a noninfectious genetic disease for which the effecting biomolecule is known comprising administering to an animal a therapeutically effective amount of an oligonucleotide identified in accordance with claim 1.

30 88. A method of treating a noninfectious genetic disease for which the effecting biomolecule is known comprising administering to an animal a therapeutically

WO 93/05182

PCT/US92/07489

- 59 -

effective amount of an oligonucleotide identified in
accordance with claim 10.

89. A method of treating a noninfectious genetic
disease for which the effecting biomolecule is known
5 comprising administering to an animal a therapeutically
effective amount of an oligonucleotide identified in
accordance with claim 19.

90. A method of treating a noninfectious genetic
disease for which the effecting biomolecule is known
10 comprising administering to an animal a therapeutically
effective amount of an oligonucleotide identified in
accordance with claim 27.

91. A method of treating a noninfectious genetic
disease for which the effecting biomolecule is known
15 comprising administering to an animal a therapeutically
effective amount of an oligonucleotide identified in
accordance with claim 38.

92. A method of treating a noninfectious genetic
disease for which the effecting biomolecule is known
20 comprising administering to an animal a therapeutically
effective amount of an oligonucleotide identified in
accordance with claim 41.

93. A method of treating a noninfectious genetic
disease for which the effecting biomolecule is known
25 comprising administering to an animal a therapeutically
effective amount of an oligonucleotide identified in
accordance with claim 50.

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US92/07489

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C12 Q 1/68

US CL :435/6, 91, 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91, 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog files 5, 73, 76, 125, 340, 144, 155, 156, 305, 350, 351, 357, 358, 399, 434, 442, 444.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Antiviral Research, vol. 16, issued 1991, Kmetz et al., "Vmw65 phosphorothioate oligonucleotides inhibit HSV KOS replication and Vmw65 protein synthesis" p. 173-184. See the entire document.	1-93
Y	Proceeding of the National Academy of Science, USA, Vol. 86, issued October 1989, AGRAWAL et al., "Inhibition of Human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues", p. 7790-7794. See the entire documents.	1-93
Y	Gene, Vol. 81, issued 1989, Groger et al., "Directional antisense and sense cDNA cloning using Epstein- Barr virus episomal expression vectors", p. 285-294. See the entire document.	1-93
Y	Science, Vol. 249, issued 03 August 1990, Tuerk et al., "Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase", p.505-510. See the entire document.	1-93



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

*T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention

*A

document defining the general state of the art which is not considered to be part of particular relevance

*X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*E

earlier document published on or after the international filing date

*L

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

*Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

*O

document referring to an oral disclosure, use, exhibition or other means

*P

document published prior to the international filing date but later than the priority date claimed

*G

document member of the same patent family

Date of the actual completion of the international search

11 DECEMBER 1992

Date of mailing of the international search report

28 DEC 1992

 Name and mailing address of the ISA/
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

AMELIA B. YARBROUGH

Telephone No. (703) 308-0196